IMC Chicago’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.54M Buy
42,400
+7,800
+23% +$491K ﹤0.01% 2919
2026
Q2
$1.98M Buy
34,600
+3,800
+12% +$208K ﹤0.01% 3047
2026
Q1
$1.74M Buy
30,800
+5,700
+23% +$332K ﹤0.01% 2717
2025
Q4
$1.49M Buy
25,100
+5,200
+26% +$283K ﹤0.01% 2648
2025
Q3
$1.08M Sell
19,900
-900
-4% -$51.5K ﹤0.01% 2659
2025
Q2
$1.14M Buy
+20,800
New +$1.22M ﹤0.01% 2393
2023
Q3
– Sell
-10,100
Closed -$875K – 1591
2023
Q2
$875K Buy
+10,100
New +$950K ﹤0.01% 1089
2023
Q1
– Sell
-14,200
Closed -$1.47M – 1286
2022
Q4
$1.47M Sell
14,200
-3,800
-21% -$357K ﹤0.01% 907
2022
Q3
$1.53M Buy
+18,000
New +$1.6M ﹤0.01% 818
2022
Q1
– Sell
-34,800
Closed -$3.08M – 1093
2021
Q4
$3.08M Sell
34,800
-11,000
-24% -$908K ﹤0.01% 715
2021
Q3
$3.54M Sell
45,800
-3,400
-7% -$268K ﹤0.01% 700
2021
Q2
$4.1M Sell
49,200
-14,800
-23% -$1.17M 0.01% 625
2021
Q1
$4.83M Buy
64,000
+26,200
+69% +$2.14M 0.01% 578
2020
Q4
$3.32M Buy
+37,800
New +$3M ﹤0.01% 632
2019
Q1
– Sell
-8,700
Closed -$741K – 654
2018
Q4
$741K Buy
+8,700
New +$828K ﹤0.01% 511

Other funds holding BMRN

IMC Chicago's BMRN Position: Q3 2026 in Review

IMC Chicago increased its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q3 2026, buying an estimated $129K and bringing the position to 11,512 shares worth $691K. The position accounts for ﹤0.01% of the portfolio, ranked #4335.

IMC Chicago first reported a position in BMRN in Q4 2018 and has held it in 7 quarters since. The position peaked at $1.82M in Q1 2021. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • IMC Chicago held 11,512 shares of BioMarin Pharmaceuticals worth $691K as of Q3 2026.
  • IMC Chicago bought 2,045 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $129K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #4335 holding.
  • IMC Chicago first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 7 quarters since.
  • IMC Chicago's BioMarin Pharmaceuticals position peaked at $1.82M in Q1 2021.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.